US based but China focused small cap biopharmaceutical stockCASI Pharmaceuticals (NASDAQ: CASI) is up around 78% over the last three trading days on no apparent news on the newswires as the following chart illustrates:
CASI Pharmaceuticals is a U.S. based, late-stage small cap biopharmaceutical company focused on the acquisition, development and commercialization of innovative therapeutics....More>>>
10 Worst States for Depression Among the College Educated
5 New DOL Fiduciary Rule Standards Delay Facts
Let Clients Figure the Retirement Funding Catastrophe Out for Themselves
President Donald Trump told Republican senators on Tuesday he supports an Affordable Care Act individual major medical market stabilization bill offered by Republican Lamar Alexander and Democrat Patty....More>>>
January 10, 2017: Markets opened mixed again Tuesday as the blue chips got off to a slow start. The DJIA peake in the middle of the day and slid back into the red with about an hour left this afternoon. The Nasdaq even posted another all-time high at 5,564.25 early this afternoon. Healthcare and financials were leading sectors while real-estate and energy lagged. WTI crude oil for February delivery....More>>>
Is Facebook Inc stock a good buy near its all-time high price? Flickr
Shares of Menlo Park, California-basedFacebook Inc.(NASDAQ:FB)are on a roll in 2017, gaining more than 21% YTD after a lackluster 2016. FB stock is trading near its all-time high of $139.68. FB stock has been driven by multiple factors. At large, the strong bullish rally has been on account of strong revenue growth....More>>>
The volatility index, or VIX once again closed under 12 percent last Friday. It has hovered in the range of 10-13 percent for the entirety of 2017 after it collapsed from a high in the low twenties following the Presidential election.
That seems like eons ago, right? And with this low volatility comes frustration for those sitting on the sidelines waiting to get involved with the stock....More>>>
Snapchat's parent company may have been a punchline for financial journos last year, but Snap (NYSE:SNAP) is turning into the comeback kid of 2019. Snap stock has now more than doubled this year, hitting that juicy milestone on Thursday afternoon after a welcome analyst upgrade.
Highlights: - Revenue growth led by higher exports and better pricing - Addition of Thionyl Chloride capacity aids vertical integration - Stablising pricing, better product mix and retail exposure positive for margin -------------------------------------------------